Literature DB >> 26377143

Tuberculosis.

Keertan Dheda1, Clifton E Barry2, Gary Maartens3.   

Abstract

Although the worldwide incidence of tuberculosis has been slowly decreasing, the global disease burden remains substantial (∼9 million cases and ∼1·5 million deaths in 2013), and tuberculosis incidence and drug resistance are rising in some parts of the world such as Africa. The modest gains achieved thus far are threatened by high prevalence of HIV, persisting global poverty, and emergence of highly drug-resistant forms of tuberculosis. Tuberculosis is also a major problem in health-care workers in both low-burden and high-burden settings. Although the ideal preventive agent, an effective vaccine, is still some time away, several new diagnostic technologies have emerged, and two new tuberculosis drugs have been licensed after almost 50 years of no tuberculosis drugs being registered. Efforts towards an effective vaccine have been thwarted by poor understanding of what constitutes protective immunity. Although new interventions and investment in control programmes will enable control, eradication will only be possible through substantial reductions in poverty and overcrowding, political will and stability, and containing co-drivers of tuberculosis, such as HIV, smoking, and diabetes.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26377143     DOI: 10.1016/S0140-6736(15)00151-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  155 in total

1.  Association between Tuberculosis, Statin Use, and Diabetes: A Propensity Score-Matched Analysis.

Authors:  Min-Chul Kim; Sung-Cheol Yun; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

Review 2.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

3.  False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes.

Authors:  Grant Theron; Rouxjeane Venter; Liezel Smith; Aliasgar Esmail; Philippa Randall; Vishesh Sood; Suzette Oelfese; Greg Calligaro; Robin Warren; Keertan Dheda
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

4.  A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment.

Authors:  Denise Kirschner; Elsje Pienaar; Simeone Marino; Jennifer J Linderman
Journal:  Curr Opin Syst Biol       Date:  2017-05-22

5.  Genetic Diversity of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in the Capital of Iran, Revealed by Whole-Genome Sequencing.

Authors:  Farzam Vaziri; Thomas A Kohl; Hasan Ghajavand; Mansour Kargarpour Kamakoli; Matthias Merker; Shima Hadifar; Sharareh Khanipour; Abolfazl Fateh; Morteza Masoumi; Seyed Davar Siadat; Stefan Niemann
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

6.  Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients.

Authors:  Mi Ra Ryu; Min-Seung Park; Eun Hye Cho; Chul Won Jung; Kihyun Kim; Seok Jin Kim; Ha Young Oh; Wooseong Huh; Hye Ryoun Jang; Won-Jung Koh; Hye Yun Park; Young-Ho Kim; Dong Hyun Sinn; Jin-Oh Choi; Jae-Won Joh; Jong Man Kim; Sung Joo Kim; Jae Berm Park; Eun-Suk Kang
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

7.  The antibacterial prodrug activator Rv2466c is a mycothiol-dependent reductase in the oxidative stress response of Mycobacterium tuberculosis.

Authors:  Leonardo Astolfi Rosado; Khadija Wahni; Giulia Degiacomi; Brandán Pedre; David Young; Alfonso G de la Rubia; Francesca Boldrin; Edo Martens; Laura Marcos-Pascual; Enea Sancho-Vaello; David Albesa-Jové; Roberta Provvedi; Charlotte Martin; Vadim Makarov; Wim Versées; Guido Verniest; Marcelo E Guerin; Luis M Mateos; Riccardo Manganelli; Joris Messens
Journal:  J Biol Chem       Date:  2017-06-15       Impact factor: 5.157

Review 8.  Ecology and evolution of Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux
Journal:  Nat Rev Microbiol       Date:  2018-02-19       Impact factor: 60.633

9.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.

Authors:  Peter C Ray; Margaret Huggett; Penelope A Turner; Malcolm Taylor; Laura A T Cleghorn; Julie Early; Anuradha Kumar; Shilah A Bonnett; Lindsay Flint; Douglas Joerss; James Johnson; Aaron Korkegian; Steven Mullen; Abraham L Moure; Susan H Davis; Dinakaran Murugesan; Michael Mathieson; Nicola Caldwell; Curtis A Engelhart; Dirk Schnappinger; Ola Epemolu; Fabio Zuccotto; Jennifer Riley; Paul Scullion; Laste Stojanovski; Lisa Massoudi; Gregory T Robertson; Anne J Lenaerts; Gail Freiberg; Dale J Kempf; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Kevin D Read; Simon R Green; Paul G Wyatt; Tanya Parish
Journal:  ACS Omega       Date:  2021-01-13

10.  Cancer Progress and Priorities: Lung Cancer.

Authors:  Matthew B Schabath; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.